Crinetics Pharmaceuticals Inc

-0.64 (-3.96%)
4:10:35 PM EDT: $15.53 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)837.19M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.14 Million
Adjusted EPS-$0.84
See more estimates
10-Day MA$16.80
50-Day MA$18.97
200-Day MA$18.91
See more pivots

Crinetics Pharmaceuticals Inc Stock, NASDAQ:CRNX

10222 Barnes Canyon Road, Building 2, San Diego, California 92121
United States of America
Phone: +1.858.450.6464
Number of Employees: 210


Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.